Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases and develop medicines.
Let’s take a stroll down memory lane...
The pilot phase of the NL Genome Project receives approval from the Health Research Ethics Board.
The Supreme Court of Newfoundland and Labrador ruled in favour of Sequence Bio and stated that the HREA Act requires that decisions on health research applications must occur within 30 days.
Sequence Bio’s NB Genome Project - Pilot receives approval from Veritas, a nationally recognized ethics review board of Canadian genomics and ethics experts.
Newfoundland and Labrador’s Research Ethics Board announces the creation of a subcommittee specific to genetic / genomics research.
Genomics expert Dr. Michael S. Phillips joins the Sequence team as Chief Scientific Officer.
Sequence Bio wins Community Impact and Business Excellence awards at the St. John's Board of Trade Awards.
Sequence Bio CEO, Chris Gardner, appointed to the newly created federal Health/Bio-sciences Economic Strategy Table by the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development.
Dr. Kathy Hudson is named Chair of our Scientific Advisory Board.
Bill S201 is passed in Canada, ensuring protection from genetic discrimination. Sequence Bio worked with former Senator Jim Cowan to support this important piece of legislation.
Sequence Bio reaches 20 employees (plus one loveable pup)!
The Sequence team moves into a new and expanded office space in St. John’s, Newfoundland & Labrador (on the oldest street in North America in fact!).
Dr. Gerry Mugford joins Sequence Bio as Director of Research. Dr. Mugford is Director of Clinical Epidemiology and an Associate Professor of Medicine and Psychiatry at Memorial University.
AWSis launched in Canada and Sequence Bio is a featured client!
Chris Gardner, CEO & President, and Karen Moores, VP Public Affairs, head to Ottawa to advocate on behalf of Bill S-201 with Honourable Senator Jim Cowan to prevent genetic discrimination.
Stanford’s Dr. Euan Ashley joins our Scientific Advisory Board and James Hardiman from DCVC joins our Board of Directors - both bringing unmatched expertise to the team.
$3 million USD seed financing led byDCVCis raised by Sequence Bio, the first Silicon Valley financing of this kind in Atlantic Canada.
Sequence Bio attends the New England Governors - Atlantic Canadian Premiers Summit in Boston, MA.
DNA Genotekand Sequence Bio enter into a supply agreement for custom DNA collection kits to use in the future.
Mark Dobbin and Dr. Andrew Furey join our Board of Directors to offer their guidance to help achieve our goal of enabling better healthcare across Newfoundland and Labrador.
Master licensing agreement with Memorial University is signed to help advance drug discovery research.
Sequence Bio and the Government of Newfoundland and Labrador sign a MOU to launch a large-scale precision medicine initiative in the future.
Dr. Pek Lum of Capella Bioscience joins the Sequence Bio Scientific Advisory Board.
$1,000,000 Seed Round of Financing closes, led by Killick Capital, Pelorus Venture and Klister Capital Corp.
Sequence Bio completes the Canadian Trade Accelerator program at the Cambridge Innovation Centre in Boston, MA.
Sequence Bio is founded!
Sequence Bio 139 Water Street, 2nd Floor St. John's, NL, A1C 1B2, Canada +1.800.296.3481